Protective role of protein C inhibitor in monocrotaline‐induced pulmonary hypertension

• Published in: Journal of thrombosis and haemostasis Vol. 4; no. 11; pp. 2331 - 2339
• Main Authors: NISHII, Y., GABAZZA, E.C., FUJIMOTO, H., NAKAHARA, H., TAKAGI, T., BRUNO, N., D'ALESSANDRO‐GABAZZA, C. N., MARUYAMA, J., MARUYAMA, K., HAYASHI, T., ADACHI, Y., SUZUKI, K., TAGUCHI, O.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.11.2006
• Subjects: Animals; Bronchoalveolar Lavage Fluid; coagulation; fibrinolysis; Humans; Hypertension, Pulmonary - chemically induced; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - genetics; Hypertension, Pulmonary - metabolism; Hypertension, Pulmonary - pathology; Hypertension, Pulmonary - prevention & control; Intercellular Signaling Peptides and Proteins - metabolism; Lung - metabolism; Lung - pathology; Mice; Mice, Transgenic; Monocrotaline - pharmacology; Monocrotaline - toxicity; Protein C Inhibitor - genetics; Protein C Inhibitor - metabolism; Protein C Inhibitor - therapeutic use; protein C pathway; pulmonary hypertension; Thrombin - metabolism

Background: Protein C inhibitor (PCI) plays a role in multiple biological processes including fertilization, coagulation, fibrinolysis and kinin systems. Objectives: We hypothesized that PCI participates in the pathogenesis of pulmonary hypertension. To demonstrate this, we compared the development...